ATTD 2021 (the 14th conference on Advanced Technologies & Treatments for Diabetes) is currently in progress. This is one of the international conferences where some of the latest developments in diabetes management are presented. We see information about new products, the results of research studies, etc. I’m honoured to be a delegate to this year’s …
Lantus is a long-acting basal insulin which has been around since 2000. That’s about to change, but don’t panic. Essentially it’s just a name change. History Lantus is a U100 form of insulin glargine, made by Sanofi. Its patent protection eventually ran out, so new versions started appearing from other companies. Lilly (who also make Humalog) …
In the October update to the Australian PBS (Pharmaceutical Benefits Scheme), another insulin arrived today. Well, sort of. The addition is Semglee, which is a “biosimilar equivalent” to Lantus. Like Lantus it’s insulin glargine. Lantus is one of the commonly-used long-acting (or “basal”) insulin used for daily injections. It’s been around for years (I used …
As I’ve previously written, the “ultra-fast” insulin Fiasp from Novo was added to PBS’s schedule as of June 1 2019. But everyone was surprised when we found it was only going to be supplied in two forms: vial and pre-filled pen. Incidentally, a year ago I spelt out the common usage of terms such as “vial”, “pen …
Well as I expected, lots has been happening in the diabetes tech world while I’ve been away working on the African photographic expedition. So this post is a little bit of a catch-up. Ryzodeg At the start of August the Australian PBS was updated to include Novo’s Ryzodeg insulin. Although Novo’s long-acting Tresiba is not …
In April there was big news as Sanofi’s long-acting Toujeo U300 insulin was added to the Pharmaceutical Benefits Scheme (PBS) and thus became accessible to many people. It had received TGA approval some time beforehand and was available under private prescription, but the cost was significant. But at the time I failed to mention another new …